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Abstract  
Background: The implantable cardioverter defibrillators (ICDs) are increasingly being used as a 
treatment modality for life threatening tachyarrhythmia. The purpose of this study was to 
compare the frequency of complications and mortality between single-chamber and dual-
chamber ICD implantation in Shahid Rajaie cardiovascular center.
Methods and results: Between January 2000 and December 2004, 234 patients received ICD by 
a percutaneous transvenous approach and were followed for 33 ± 23 months. The cumulative 
incidence of complications was 9.4% over the follow-up period. There was no significant 
difference in overall complication rate between single chamber (VR) and dual chamber (DR) 
ICD groups in the follow-up period (P= 0.11). The risk of complications did not have any 
statistically significant difference in secondary versus primary prevention groups (P=0.06). The 
complications were not associated with the severity of left ventricular systolic dysfunction 
(P=0.16).The frequency of lead-related complications was higher in dual chamber ICDs in 
comparison with single chamber ICDs (P=0.02). There was no significant difference in mortality 
between different sex groups (P=0.37), different indications for ICD implantation (P=0.43) or 
between VR and DR ICD groups (P= 0.55). Predictors of mortality were NYHA class III or more 
(P<0.001), age >65 years (P=0.011) and LVEF<30% (P<0.001). The mortality in patients with 
CAD and DCM were significantly higher than those with other structural heart diseases 
(P=0.001).
Conclusions: Close monitoring of patients during the first 2 month after ICD implantation is 
recommended   because   the   majority   of   complications   occur   early   after   the   procedure.
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Introduction
               The implantable cardioverter defibrillators (ICDs) are increasingly being used as a 
treatment   modality   for   high   risk  s urvivors   of   life-threatening  tachyarrhythmia.1,2  Major 
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technological advances like the introduction of transvenous defibrillation leads and "active can" 
concept have simplified the implantation of ICDs and have reduced implantation-related 
complications   but   still   there   are   considerable   rate   of   complications   in   most   of   the 
electrophysiologic centers.3,4
              The purpose of the current study was to identify and characterize prospectively the 
frequency of lead and implant-related complications and also mortality in patients with single-
chamber versus dual-chamber ICD implantation.
Methods
Patients:  
            Between January, 2000 and December, 2004, 234 patients received ICDs in our center. 
All of them included in the study and were followed for 33 ±23 months. The primary end point 
of the study was actuarial survival. The secondary end point was nonfatal complications, 
including inappropriate ICD therapy, lead-related and implant-related complications. The study 
was approved by local Ethics Committee and written informed consent was obtained from all the 
patients.
Implanted ICDs and programming:
               ICD system manufacturers included Medtronic and St Jude systems in 160 and 75 
patients respectively. Atrial leads included 1688 T or 1642T for St Jude and 5076 for Medtronic 
systems. Ventricular leads included 1570,1572,1571,1580 and 1581 for St Jude and 6944, 6947 
and 6948 for Medtronic systems. All of the ventricular leads were bipolar. In implanted devices 
all the detection and discrimination criteria were activated with the nominal values. In all the 
devices we defined ventricular fibrillation zone (300ms) plus one VT zone (400 ms). If the 
patient had an episode of spontaneous or induced sustained monomorphic VT slower than 370 
ms we extended the VT zone to VT cycle length plus 40ms. In the VT detection zone the first 
therapy was three antitachycardia burst pacing. We used the nominal values of the ICDs for the 
duration and tachyarrhythmia detection criteria. Antibradycardia pacing was programmed in VVI 
mode with pacing rate of 40 beats per minute in all VR and DR ICDs, unless the patients needed 
dual   chamber   pacing,   those   with   long   QT   syndrome   and   hypertrophic   obstructive 
cardiomyopathy.
Implantation techniques:
               The implantation routes were either subclavian or Axillary veins percutaneously in 
electrophysiology laboratory by an electrophysiologist.
Follow-up protocol:
            The patients were followed after 1 month postoperatively and every 3 months thereafter 
and upon receiving high voltage therapy in our outpatient ICD clinic. ICD evaluations during 
follow-up visits included routine clinically appropriate measurements including interrogation of 
the device for tachyarrhythmia episodes, evaluation of sensing and pacing thresholds and lead 
impedance. Floppy diskettes were used to retrieve all episodes of ICD therapy. All the episodes 
resulted in ICD therapy, studied independently by two electrophysiologists to define the 
diagnosis. All the episodes were categorized as appropriate or inappropriate. ICD-related 
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complications were documented, as were mortality and cause of death. Chest radiography (CXR) 
was obtained before hospital discharge and every 6 months to confirm radiographic lead 
integrity. Clinical evaluation of patients included history and physical examination of the 
implantation site. Complications were defined as unexpected adverse events that were felt to be 
related to the implant procedure or to the ICD lead and generator system.
Statistical analysis:
               Baseline characteristics and complications were summarized as the mean ± SD for 
continuous variables and otherwise as percentage. SPSS 13 software (SPSS Inc., Chicago, IL, 
USA) was used for data storage and analysis. Qualitative characteristics were compared using the 
Pearson’s chi square and Fischer exact tests. Kaplan-Meyer survival curves were calculated. Log 
rank statistics were used to compare the distribution of time to complications and mortality 
between different ICD groups. Two-tailed P < 0.05 were considered significant. Regression 
analysis was performed to evaluate the effect of variables on mortality and complications.
Results
Baseline characteristics:
            Baseline characteristics of the patients are summarized in Table 1. Table 2 compares the 
baseline characteristics of the patients in VR and DR ICD groups.
Table1: Baseline characteristics of patients
CAD= Coronary artery disease, DCM= Dilated cardiomyopathy,
HCM= Hypertrophic cardiomyopathy, NYHA= New York Heart Association
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Table2: Comparison of baseline characteristics between single and dual chamber devices.
ICD-VR= Single chamber implantable cardioverter-defibrillator, ICD-DR=Dual 
chamber implantable cardioverter-defibrillator, LVEDd= Left ventricular end 
diastolic diameter, LVESd= Left ventricular end systolic diameter, LVEF= Left 
ventricular ejection fraction, NYHA= New York Heart Association, CAD= 
Coronary artery disease, DCM= Dilated cardiomyopathy, HCM= Hypertrophic 
cardiomyopathy.
Mortality:
            Three patients (1.2%) died during the first month after ICD implantation because of 
multi-organ failure, massive pulmonary emboli and acute coronary syndrome.   The 1-year 
survival rate was 94.9% and 94.1% for VR and DR ICDs respectively. The overall survival rate 
during follow-up was 90.6% and 88.9% for VR and DR ICDs respectively. There was no 
significant difference in mortality between different sex groups (P=0.37), different indications 
for ICD implantation (P=0.43) or between VR and DR ICD groups (P= 0.55) (Figure  1). 
Univariate regression analysis showed predictors of mortality as NYHA class III or more 
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(P<0.001), age >65 years (P=0.011) and LVEF<30% (P<0.001). The mortality in patients with 
CAD and DCM were significantly higher than those with other structural heart diseases 
(P=0.001). During the follow-up, 59 patients (25.2%) had at least one inappropriate ICD therapy. 
The mortality of this group was significantly higher than those who had not experienced 
inappropriate therapy (P=0.03).
Figure 1: Kaplan-Meier plot of the cumulative survival according to ICD 
type. Log rank (Mantel-Cox) test was used to generate the P value. ICD-
VR=   Single-chamber   implantable   cardioverter-defibrillator;   ICD-
DR=Dual--chamber implantable cardioverter-defibrillator.
Complications:    
            Overall, 22 patients (9.4%) suffered from ICD-related complications during follow-up 
period. There was no significant difference in overall complication rate between VR and DR ICD 
groups in the follow-up period (P= 0.11) (Figure 2). The risk of complications was not 
associated with any patient-specific factor including age (P=0.32) and gender (P=0.19) (Table 
1). The risk of complications did not have any statistically significant difference in secondary 
versus primary prevention groups (P=0.06). The complications were not associated with the 
severity of left ventricular systolic dysfunction (P=0.16). Also, no statistically significant 
difference was observed between different NYHA classes (P=0.45) and underlying heart diseases 
(P=0.06). During the follow-up, 59 patients (25.2%) had at least one inappropriate ICD therapy. 
The risk of complications did not have any statistically significant difference in this group with 
those who had not experienced inappropriate therapy (P=0.16). The comparison of complications 
in different models of implanted leads was not possible due to variety of the models and small 
numbers of each model.
Implant-related complications:
            Implant-related complications occurred in 13 patients (5.5%). Hematoma or bleeding was 
the most frequent complication in this group, found in 7 patients (3%). Pneumothorax and 
hemothorax were found in 3(1.3%) and 2(0.9%) patients, all of them managed with chest tube 
insertion. No significant pocket infection was found but only one patient suffered from stitch 
abscess, treated conservatively with antibiotics.
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Lead-related complications:
            Lead-related complications occurred in 9 patients (3.8%). Lead dislodgement was the 
most frequent lead-related complication, found in 5 patients (2.1%). Dislodgement of ventricular 
and atrial leads was seen in 3 and 2 patients respectively. Lead fracture was found in 2 patients 
(0.9%).6 Exit block and insulation break was rare, each of them occurred only in 1 patient 
(0.4%). 4 of 5 lead dislodgements and all of hematomas occurred in the 2 month of implantation. 
No cardiac perforation was found. The frequency of lead-related complications was significantly 
higher in dual chamber ICDs in comparison with single chamber ICDs (P=0.02).
Figure 2: Kaplan-Meier plot of the complication-free survival according 
to ICD type. Log rank (Mantel-Cox) test was used to generate the P value. 
ICD-VR=   Single-chamber   implantable  cardioverter-defibrillator;  ICD-
DR=Dual--chamber implantable cardioverter-defibrillator.
Discussion
               This   prospective  study  characterized  the  incidence  of   lead  and  implant-related 
complications and mortality of ICD implantations in our center. The baseline demographic data 
of the patients in this study were comparable to large studies (Table1).3-8 With the downsizing of 
ICD pulse generators, pectoral implantation has become standard for ICD placement.9 Older 
generation pacemakers of comparable size to ICD pulse generators had a significant risk of 
erosion and other pocket complications.10 During this study, 234 consecutive ICD implantations 
over a 33 ±23 months follow-up showed low (9.4%) incidence of complications. The most 
common implant and lead related complications were hematoma and lead dislodgement which 
was found in 3% and 2.1% of patients. These findings are consistent with or even rarer than prior 
report.5-18 In the majority of previous studies the ICD-related complications did not differ with 
increasing age which was consistent with this study.15-18 The infection rate in this case series was 
very low (0.4%). In large studies, infection rates of 1.3-2.7% were reported. Because most of the 
infections that were seen in previous reports occurred with abdominal pocket, it seems 
reasonable  to  expect  a  lower   infection  rate  with  current  generation  of   ICDs  implanted 
transvenously in the pectoral region.7, 20-22 Intensive use of prophylactic antibiotics before and 48 
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hours after the procedure and avoidance of cauterization for hemostasis may help us reduce the 
infection rate.
           Some authors encourage the usage of cephalic vein cut downs as the preferred approach 
for ICD lead venous approach for prevention of vascular complications of blind, percutaneous 
subclavian venipuncture such as pneumothorax and hemothorax.23,24 The time course of specific 
complications reinforces the need for continued lead surveillance in ICD patients. Although 
bleeding, pneumothorax, lead dislodgement and infection tends to occur soon after implant, lead-
related problems such as lead fracture and insulation breaks tend to occur throughout follow-up.7-
19,25,26 
Limitations
            The present study must be interpreted in light of certain methodological limitations. The 
ICDs were implanted with multiple operators of variable training and experience. Therefore, the 
effects of differences in experience or surgical technique on complication rates were not 
controlled.  However, the inclusion of the large number of cases and relatively long follow-up 
periods makes it more likely that these results are reliable. The second limitation was lack of 
cooperation of some patients for regular follow-up and routine CXRs. Therefore, the incidence of 
lead fractures and insulation breaks may have been underestimated. Also, small hematomas 
usually managed by sand bag and under- reported.
Conclusion
            This study showed that the pectoral implantation of ICDs by electrophysiologists in our 
center has a low rate of complications, comparable with most of the qualified centers. Since most 
of implant-related and some of lead-related complications occur soon after the implant, close 
early monitoring of patients during first 2 month after implantation is recommended. The 
continued occurence of lead fractures and the need for premature system revision over time 
supports the practice of close, routine ICD surveillance. Vascular complications of blind 
percutaneous subclavian venipuncture could be avoided if cephalic vein cut down is used for 
ICD lead venous access.
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